Colorectal Cancer
Latest News
October 20th 2025
With a median follow-up of 50.1 months, nivolumab plus ipilimumab achieved a median PFS of not reached compared with 60.8 months with nivolumab monotherapy in this CRC population.
More News
COMING SOON: Around the Practice: ctDNA Analysis to Direct Treatment Decisions in Colorectal Cancer
June 28th 2023Tanios S. Bekaii-Saab, MD, provides a look at an upcoming Cancer Network Around the Practice program in which a panel of experts will present the case of a patient with colorectal cancer, review updates from clinical trials, and provide insights on the role of ctDNA in treatment decision-making.
FDA Approves FoundationOne LiquidCDx for Encorafenib Combo in mCRC
June 12th 2023The FDA’s approval of the FoundationOne Liquid CDx as a companion diagnostic may improve access to treatment with encorafenib plus cetuximab for patients with metastatic colorectal cancer harboring a BRAF V600E alteration.
![“We think that we can successfully de-escalate treatment of rectal cancer and achieve the same high cure rates [and] keep patients disease free, with less long-term toxicity and effects,” lead author Deb Schrag, MD, FASCO, MPH, said.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F852c505e728c0e9c7b27981b616ac51a65af1503-1200x800.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“We think that we can successfully de-escalate treatment of rectal cancer and achieve the same high cure rates [and] keep patients disease free, with less long-term toxicity and effects,” lead author Deb Schrag, MD, FASCO, MPH, said.")
Preoperative FOLFOX Appears Noninferior Vs CRT in Rectal Cancer
June 4th 2023“We think that we can successfully de-escalate treatment of rectal cancer and achieve the same high cure rates [and] keep patients disease free, with less long-term toxicity and effects,” lead author Deb Schrag, MD, FASCO, MPH, said.
Tucatinib/Trastuzumab Yields Durable Responses in HER2+ Metastatic CRC
June 2nd 2023Tucatinib plus trastuzumab represents a valuable, novel option for HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer that is chemotherapy refractory, according to the authors of the phase 2 MOUNTAINEER trial.
Colorectal Cancer: Insights on ctDNA and Retesting for HER2 Expression
A panel of experts discuss the role of ctDNA and their practices for retesting HER2 expression to guide treatment for colorectal cancer.
Patient Profile: A 40-Year-Old Woman With Colorectal Cancer
Experts on colorectal cancer present the case of a 40-year-old woman with CRC, who receives later-line treatment with trastuzumab deruxtecan, and share their initial thoughts.
Patient Profile: A 47-Year-Old Woman With HER2+ CRC and Early Disease Progression
Expert oncologists present the case of a 47-year-old woman with colorectal cancer and early disease progression, and discuss treatment options with the ongoing MOUNTAINEER-03 study.
Overview of HER2+ Metastatic Colorectal Cancer
Expert oncologists discuss the landscape surrounding HER2+ metastatic CRC, including recommendations for biomarker testing and an overview of scoring criteria.
Patient Profile: A 46-Year-Old Woman With HER2+ Metastatic Colorectal Cancer
A panel of expert oncologists present the case of a 46-year-old woman with HER2+ metastatic colorectal cancer, who is treated with tucatinib in the second-line setting.
Allele Fractions Reliable Surrogate for Tumor Burden Following BRAFi in CRC
April 6th 2023Progression-free survival and overall survival appear to be worse in patients with metastatic colorectal cancer who have a high- vs low-BRAF allele fraction after treatment with a BRAF inhibitor plus an anti-EGFR agent plus or minus a MEK inhibitor.
